



ABN 53 075 582 740

ASX ANNOUNCEMENT
28 October 2019

Quarterly Cashflow Report

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today released its Appendix 4C - Quarterly Cashflow Report. During the quarter:

- The Company received a further A\$1,324,459.29 R&D Tax Incentive Refund for the 2017/2018 financial year, plus interest of \$17,593.18.
- Following a positive meeting with the FDA, we submitted an application for Fast Track designation for BNC210 for the treatment of Post-Traumatic Stress Disorder (PTSD). Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions that fulfill an unmet medical need.
- The Company received positive results from a pharmacokinetic study in healthy volunteers using the newly developed solid dose formulation of Bionomics' lead drug candidate, BNC210. The results demonstrated that the solid dose of BNC210 achieved the blood levels necessary to meet the primary endpoints for effectiveness for treating PTSD patients in future clinical trials. These results support the further development of BNC210 for the treatment of PTSD.
- We continue to assess the strategic options for partnering and portfolio prioritisation whilst protecting our major assets and conserving cash. The feasibility of funding a second clinical trial of BNC210 is currently being assessed.
- The Company continues to advance other pre-clinical assets in its research pipeline.
- Cash balance at 30 September 2019 was \$9.36 million (30 June 2019: \$13.98 million) with net operating cash outflow during the quarter ended 30 September 2019 of \$2.56 million.
- Cash receipts for the quarter ending 30 September 2019 were mainly related to receipts from customers of \$1.03 million (30 June 2019: \$1.92 million), Tax Incentive Refund of \$1.33 million and Foreign Government Grants of \$0.78 million.
- Research & development costs decreased by 49% compared to the previous quarter.

Whilst section 9 of the Appendix 4C shows the estimated cash outflows for the quarter ending 31 December 2019, no estimated cash inflows are provided. The estimated cash outflows are reliant on the timing of various activities, including clinical trials, being conducted by Bionomics.

Upcoming Milestones:

- The Annual General Meeting of the Company will be held on Wednesday 20 November 2019.
- Bionomics expects to receive the FDA's response to our application for Fast Track designation for BNC210 in CY4Q 2019.

- Whilst the internal focus and current R&D spend is restricted to CNS programs, Bionomics continues limited activities to maximise the value of its legacy oncology programs through divestment and/or out-licensing of both BNC101 and BNC105.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Ltd.

Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6100
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC101 and BNC105), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Bionomics Limited

ABN

53 075 582 740

Quarter ended ("current quarter")

30 September 2019

Consolidated statement of cash flows		Current quarter	Year to date (3 months)
		\$A'000	\$A'000
1	Cash flows from operating activities		
1.1	Receipts from customers (contract services)	1,039	1,039
1.2	Payments for		-
	(a) research and development	(2,625)	(2,625)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	(59)	(59)
	(e) staff costs	(365)	(365)
	(f) administration and corporate costs	(1,380)	(1,380)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	41	41
1.5	Interest and other costs of finance paid	(383)	(383)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	2,105	2,105
1.8	Other (provide details if material)		-
	(a) Rent received	40	40
	(b) Payments for contract services	(981)	(981)
1.9	Net cash from / (used in) operating activities	(2,569)	(2,569)
2	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(6)	(6)
	(b) businesses (see item 10)	-	-
	(c) investments	(52)	(52)
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	3	3
	(b) businesses (see item 10)	-	-
	(c) investments	550	550
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)		-
2.6	Net cash from / (used in) investing activities	495	495

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter	Year to date (3 months)
		\$A'000	\$A'000
3	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(2,561)	(2,561)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(2,561)	(2,561)
4	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	13,985	13,985
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,569)	(2,569)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	495	495
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(2,561)	(2,561)
4.5	Effect of movement in exchange rates on cash held	12	12
4.6	Cash and cash equivalents at end of quarter	9,363	9,363
5	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter	Previous quarter
		\$A'000	\$A'000
5.1	Bank balances	9,363	13,986
5.2	Call deposits	-	-
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	9,363	13,986
6	Payments to directors of the entity and their associates	Current quarter	
		\$A'000	
6.1	Aggregate amount of payments to these parties included in item 1.2	172	
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-	
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2		
Remuneration paid to Chief Executive Officer/Managing Director and Non-Executive Directors			

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

7 Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8 Financing facilities available	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Add notes as necessary for an understanding of the position</i>		
8.1 Loan facilities	17,685	17,685
8.2 Credit standby arrangements		
8.3 Other (please specify)		

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

Silicon Valley Bank initial loan US\$7.5m and Oxford Finance LLC initial loan US\$7.5m, effective interest 9.5%, secured by substantially all of the Group's assets, other than intellectual property.

9 Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(1,282)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	(45)
9.5 Staff costs	(271)
9.6 Administration and corporate costs	(1,157)
9.7 Other (provide details if material)	
(a) Receipts from customers (contract services)	1,066
(b) Payments for contract services	(1,178)
(c) Repayment of Borrowings	(2,284)
9.8 Total estimated cash outflows	(5,150)

10 Acquisitions and disposals of business (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:
(Company Secretary)

Date: 28/10/2019

Print name: Jack Moschakis

Notes

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.